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A Missed Opportunity for Cardiovascular Risk AssessmentKi Park, MD, MS,a Pensee Wu, MBCHB, MD(RES),b,c Martha Gulati, MD, MSdA therosclerotic cardiovascular disease(ASCVD) remains a signiﬁcant cause ofmorbidity and mortality in women, with
event rates rising particularly in young women.
Women are disproportionately affected by traditional
cardiovascular (CV) risk factors such as diabetes and
hypertension compared with men. In addition to
standard risk factors, many risk factors are either fe-
male predominant, such as autoimmune conditions
and psychological stressors, or female speciﬁc, such
as hormonal changes, throughout the course of a life-
time and pregnancy-related issues. Among the most
important risk factors speciﬁc to women are condi-
tions occurring during pregnancy and history related
to fertility and gynecological conditions. The value of
such history has become more apparent in recent
literature; however, the translation of this knowledge
to clinical practice has been poor. The importance of
recognizing speciﬁc obstetric and gynecological
(OB-GYN) conditions and the speciﬁc conditions to
screen for are the focus of this editorial.
OBSTETRICS HISTORY
Pregnancy is often referred to as a “stress test” in
relation to the signiﬁcant changes in cardiac output
and associated heart rate/stroke volume that occur.
Changes in metabolic regulation also occur that,
when dysfunctional, can lead to adverse neonatal and
maternal outcomes. These conditions associated withISSN 2666-0849
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adverse pregnancy outcomes (APO) and are shown in
Figure 1 (1). APOs, including hypertensive disorders of
pregnancy and gestational diabetes, have been asso-
ciated with elevated risk of CV events, including
myocardial infarction, heart failure, and stroke.
Neonatal outcomes such as spontaneous pre-term
birth and intrauterine growth restriction are associ-
ated not only with adverse infant outcomes but also
with adverse long-term maternal CV outcomes.
Whether the association between APO and ASCVD
risk is due to underlying predisposition to ASCVD or
whether pregnancy triggers the onset of vascular
dysfunction is unknown (Figure 1). However, what
has become more readily evident is that APO not only
leads to peripartum neonatal and maternal adverse
outcomes but also is associated with signiﬁcant long-
term ASCVD risk. In this case, it is of the utmost
importance to recognize such history so that proper
screening and potential risk modiﬁcation can be
implemented. In the United States, >80% of women
experience at least 1 pregnancy. Documenting such
history provides insight into risk, and the results of
this “free” stress test can be obtained without cost by
simply asking women about their obstetric history.
Maternal recollection of events during pregnancy has
been shown to be an accurate reﬂection of obstetric
history. Recent multidisciplinary society guidelines
have acknowledged the importance of recognizing
APOs in evaluating, identifying, and potentially
modifying ASCVD risk (2). American College of Ob-
stetricians and Gynecologists (ACOG) guidelines
recommend routine screening of body mass index,
lipids, and blood pressure in all women with a history
of APO (3). Newly released American Heart Associa-
tion (AHA)/American College of Cardiology (ACC)
guidelines on blood cholesterol now include APOs as
potential “risk enhancers” in consideration of ASCVD
risk. Even among women without APOs, parity in andhttps://doi.org/10.1016/j.jaccas.2019.11.035
FIGURE 1 Potential Mechanisms for the Association Between Adverse Pregnancy Outcomes and Future Cardiovascular Disease Risk
Reprinted with permission from Wu et al. (1). CHD ¼ coronary heart disease; CVA ¼ cerebrovascular accident; CVD ¼ cardiovascular disease.
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162of itself has been associated with ASCVD risk in that
parous women compared with nulliparous women
exhibit greater ASCVD risk, which increases propor-
tionally to each live birth. Obtaining a cardio-
obstetric history is critically important to accurately
assessing ASCVD risk when women otherwise seem to
be at low risk for ASCVD.
INFERTILITY AND ASSISTED
REPRODUCTIVE TECHNOLOGY
Discussion of reproductive history should include
assessment of history of recurrent miscarriage,
infertility conditions, and use of assisted reproduc-
tive technology (ART). Some evidence suggests
that recurrent miscarriage (i.e., 3 consecutive mis-
carriages) is associated with ASCVD, and optimization
of modiﬁable ASCVD risk factors in women with this
history is recommended. Polycystic ovary syndrome
(PCOS) is a common cause of infertility affecting 5%
to 10% of women. PCOS is associated with increased
risk of hypertension, dyslipidemia, gestational dia-
betes, and type 2 diabetes, thus allowing opportu-
nities for risk screening and modiﬁcation. Therefore,
in women with PCOS, the European Society of Car-
diology (ESC) and ACOG guidelines have recom-
mended periodic screening for diabetes and ASCVD
risk factors, respectively. ART, which includes intra-
uterine insemination and in vitro fertilization, has
been associated with elevated risk of gestational hy-
pertension, pre-eclampsia, and APOs. The mechanismis unclear but may be mediated through excessive
ﬂuid shifts in the setting of ovarian activation
(referred to as ovarian hyperstimulation syndrome)
and/or hormone-related effects on endothelial func-
tion. Although a meta-analysis on this subject
concluded that there was no signiﬁcant association
between ART and CVD risk, this analysis was
composed of only 6 studies and could not make a
deﬁnitive assessment of long-term venous thrombo-
embolic risk; it also suggested an increased risk of
stroke. Furthermore, failure to conceive after ovula-
tion induction as part of ART has been associated
with increased ASCVD risk. As such, care should be
taken to inquire about ART history while further
studies investigate this potential association.
HORMONAL THERAPY
Several gynecological conditions that affect fertility
and menopause have been associated with increased
risk of ASCVD. The risk of ASCVD is known to increase
after menopause. Similarly, surgical menopause and
premature ovarian insufﬁciency (POI) are associated
with increased risks of CVD. POI occurs in approxi-
mately 1% of the female population, and current
AHA/ACC, ESC, and Dutch guidelines all recommend
optimizing modiﬁable ASCVD risk factors in this high-
risk group. Because hormone replacement therapy in
post-menopausal women is linked to increased risks
of stroke and venous thromboembolism, such therapy
in women with surgical menopause and POI should
TABLE 1 Recommended Adverse Pregnancy Outcomes and
Gynecological Conditions for Cardiovascular Disease Risk
Screening
Pregnancy history
Hypertensive disorders of pregnancy
Gestational hypertension
Pre-eclampsia
Eclampsia
Chronic hypertension
Gestational diabetes
Pre-term birth (<37 weeks)
Intrauterine growth restriction/low birth weight/small for
gestational age
Parity
Miscarriages
Assisted reproductive technology
Infertility
Gynecological history
Polycystic ovarian syndrome
Premature ovarian insufﬁciency
Use of oral contraceptives
Menopausal status
Use of hormone replacement therapy
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163continue only until the average age of menopause.
Combined oral contraceptive pills that contain estro-
gen are associated with increased risk of venous
thromboembolism and are contraindicated in women
with ischemic heart disease, cyanotic heart disease,
heart failure, or arrhythmia, and in those with pul-
monary hypertension taking endothelin receptor an-
tagonists. Contraceptive methods for women with
cardiac disease is a delicate issue that deserves spe-
cial consideration but is outside the scope of this
editorial.
FUTURE DIRECTIONS
As the value of screening for female-speciﬁc risk
factors related to OB-GYN history becomes more
widely recognized for better assessment of ASCVDrisk, the next question is which providers should be
screening for such conditions. It is imperative that
women with hypertensive disorders of pregnancy
have close follow-up in the immediate postpartum
period to assess adequate blood pressure control.
Developing a system to transition such women to
regular follow-up with a primary care physician or
cardiologist is key to preventing gaps in care. A rec-
ommended list of OB-GYN conditions to screen for is
given in Table 1. Automated referral systems post-
delivery and facilitating visits at hospital discharge
can alleviate attrition in postpartum follow-up. For
the long term, many of these young women of
childbearing age often do not have other chronic
medical conditions, so they may not routinely seek
primary care. However, a key opportunity for
screening is within OB-GYN ofﬁce visits. A signiﬁcant
number of women rely on the OB-GYN provider as
their primary care provider. Such OB-GYN visits pro-
vide a valuable opportunity to screen women for
ASCVD risk factors and to utilize OB-GYN history for
either implementation of screening or risk reduction
and/or referral to a primary care physician or cardi-
ologist (2). Such an initiative was put forth through a
partnership between the Society for Cardiovascular
Angiography and Interventions–Women in In-
novations (SCAI-WIN) and ACC in 2012, demon-
strating proof of concept for improving risk
assessment and referral. Education also needs to be
highlighted within primary care specialties in which
primary prevention can be implemented in young
women. Such innovative approaches to bridging gaps
in care are needed to capture women who are at risk.
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